Treatment of conjunctival squamous cell carcinoma with topical 5-fluorouracil

Edoardo Midena, Claudia Degli Angeli, Massimo Valenti, Valentina de Belvis, Paolo Boccato

Abstract

Aim—To evaluate the efficacy of topical 5-fluorouracil (5-FU) alone, without concurrent surgery or radiotherapy, for the treatment of conjunctival squamous cell carcinoma.

Methods—Eight patients affected by conjunctival squamous cell carcinoma (three recurrent cases, three incompletely excised, and two untreated cases) were treated with 1% 5-FU eye drops. Topical 1% 5-FU was administered four times daily for 4 weeks (one course). Clinical examination (biomicroscopy and photography) and morphological evaluation of conjunctival cytological specimens were used to monitor the efficacy of local chemotherapy, side effects, and recurrences.

Results—All patients showed clinical regression of conjunctival carcinoma after topical 1% 5-FU treatment. Neoplastic conjunctiva was completely replaced by normal epithelium within 3 months. Mean follow up was 27 months. One patient needed two courses of local chemotherapy for recurrent disease. An acute transient toxic keratoconjunctivitis was observed in all treated cases; it was easily controlled with topical therapy. No long term side effects were found.

Conclusions—Topical 1% 5-FU is effective in the treatment of recurrent, incompletely excised, and selected untreated conjunctival squamous cell carcinomas. Topical 1% 5-FU has no major complications. This study suggests that topical conjunctival chemotherapy with 1% 5-FU may be useful, at least as adjunctive therapy, in the treatment of conjunctival squamous cell carcinoma.

(Square Ocular Oncology Service, Institute of Ophthalmology, University of Padua, Padua, Italy)

Paolo Boccato

Correspondence to: Edoardo Midena, MD, Ocular Oncology Service, Institute of Ophthalmology, University of Padova, Via Giustiniani 2, 35100 Padova, Italy

Accepted for publication 22 September 1999

Table 1 Characteristics of patients with conjunctival squamous cell carcinoma

<table>
<thead>
<tr>
<th>Case No</th>
<th>Age/sex</th>
<th>Type of lesion*</th>
<th>Conjunctival site</th>
<th>Corneal involvement (Y/N)</th>
<th>Follow up (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>66/M</td>
<td>IE</td>
<td>nasal limbal</td>
<td>N</td>
<td>30</td>
</tr>
<tr>
<td>2</td>
<td>91/M</td>
<td>U</td>
<td>nasal limbal, bulbar and palpebral</td>
<td>Y</td>
<td>53</td>
</tr>
<tr>
<td>3</td>
<td>77/M</td>
<td>R</td>
<td>nasal bulbar and limbal</td>
<td>Y</td>
<td>30</td>
</tr>
<tr>
<td>4</td>
<td>78/M</td>
<td>R</td>
<td>temporal paralimbal</td>
<td>N</td>
<td>42</td>
</tr>
<tr>
<td>5</td>
<td>63/M</td>
<td>U</td>
<td>nasal limbal and bulbar</td>
<td>Y</td>
<td>23</td>
</tr>
<tr>
<td>6</td>
<td>57/F</td>
<td>R</td>
<td>nasal limbal</td>
<td>Y</td>
<td>18</td>
</tr>
<tr>
<td>7</td>
<td>60/F</td>
<td>IE</td>
<td>temporal bulbar</td>
<td>N</td>
<td>14</td>
</tr>
<tr>
<td>8</td>
<td>68/F</td>
<td>IE</td>
<td>nasal bulbar</td>
<td>N</td>
<td>13</td>
</tr>
</tbody>
</table>

*IE = incompletely excised; U = untreated; R = recurrent.

Squamous cell carcinoma is the most frequent malignant tumour of the conjunctiva. The primary treatment modality for this lesion is wide local excision and supplemental cryotherapy, with accurate histological assessment of surgical margins. However, the recurrence rate is still high, even when surgical margins of primary excision are free from malignant cells. Moreover, recurrences may be multiple and their occurrence greatly increases the risk of local spread. Local irradiation is sometimes used in conjunction with repeated excision to treat conjunctival recurrences of squamous cell carcinoma; however, side effects limit the use of supplemental irradiation.

Topical conjunctival chemotherapy with antineoplastic drugs has recently been proposed as a new approach in the treatment of conjunctival premalignant lesions (primary acquired melanosis and conjunctival intraepithelial neoplasia) with promising results.

A few years ago, after some anecdotal observations, we started a prospective non-randomised study to evaluate the efficacy of topical 5-fluorouracil (5-FU) in the treatment of recurrent, partially excised, and selected untreated (see below) conjunctival squamous cell carcinomas.

We report clinical and morphological findings seen in our patients affected by conjunctival squamous cell carcinoma treated with topical 1% 5-FU.

Patients and methods

Eight patients with conjunctival squamous cell carcinoma (CSCC) were treated with topical 5-FU (Fluoro-Uracile Roche, Roche spa, Milan, Italy) alone (Table 1). A consent statement, approved by the ethics committee, was signed by each patient. Antineoplastic eye drops were prepared by our laboratory and each patient received a new bottle of eye drops weekly during the treatment course.

All patients were examined by the senior author (EM) and were included in this study after complete eye examination and review of histopathological and/or cytological findings. Baseline histopathological specimens were available for all patients, except two who had refused surgery as a primary procedure. In these last two cases diagnosis was made examining multiple cytological smears of the affected conjunctiva. All patients underwent baseline clinical examination and photography. 5-FU 1% eye drops were prepared in aqueous solution and then administered four times daily during the course of 4 weeks. Clinical examination was performed weekly during the treatment and then after 15 days, 1, 3, and 6 months. Morphological follow up (1, 3, and 6 months after therapy) of all cases was performed using cytological smears, which were
obtained with the scraping technique. The sampling procedure was always performed by the senior author (EM) in the following manner: the area to be sampled was vigorously scraped and four or five specimens were collected from each lesion. We have previously shown that this technique allows adequate sampling of superficial and deep conjunctival cells. All patients were then followed at 6 month intervals for any evidence of clinical or morphological recurrence. At the last follow up examination a conjunctival biopsy was performed at the site of the original lesions, except for the two patients who had refused primary surgery.

Patients were instructed about local side effects. After instillation of the eye drops the inferior lacrimal punctum was briefly occluded and an eye ointment was applied on the inferior eyelid skin to minimise skin contact with the antineoplastic drug.

Results
All patients involved in this study had a minimum follow up of 13 months (range 13–53 months; mean 27 months). No patient was lost to follow up.

The patients had a mean age of 70 years (range 57–91 years); six were male and two were female. Three patients had incompletely excised primary CSCC, three patients had local recurrence of CSCC, and two patients had untreated CSCC. The mean largest diameter of the lesions (excluding the diffuse case: case 2, Table 1) was 5.6 mm (range 1–12 mm).

Local excision was not performed as a primary procedure in two cases for the following reasons: one patient was elderly (that is, 91 years old) and affected by a diffuse CSCC which was not amenable to treatment without transplantation of normal conjunctiva from the fellow eye (this case has been previously reported in detail). The second patient had CSCC in his only seeing eye and had refused surgery proposed elsewhere. In these two cases baseline diagnosis was performed on cytological smears according to standard cytological criteria of malignancy: cell atypia, loss of polarity, unfavourable nuclear/cytoplasmic ratio, dirty (necrotic) background. All other cases had histological documentation of their lesion.

The interval between the primary incomplete excision (three patients) and topical chemotherapy was 4–6 weeks. The mean interval between the primary complete excision of CSCC (three patients) and local recurrence was 22 months. All patients completed the entire course of 4 weeks of local chemotherapy. Transient conjunctivitis and superficial keratitis were observed in all patients during the third or fourth week of treatment. This side effect was easily controlled with topical drugs (artificial tears and antibiotics) in 5–6 days. Seven patients had complete and stable regression of their conjunctival lesions. One patient (case 3, Table 1) had a clinical local recurrence, in a previously involved area, 6 months after topical chemotherapy. He was successfully retreated with a new 4 week course of 5-FU without major side effects. After 19 months of follow up he remains disease free. Four patients (50%) had concomitant conjunctival and corneal involvement, both of which regressed with treatment. At the 3
No malignant cells were subsequently found, except for the recurrent case, by thorough examination of conjunctival cytological smears. Conjunctival biopsy performed during last clinical examination confirmed the cytological results (Figs 3 and 4). Figures 5 and 6 show one successfully treated case (case 2) before and after local chemotherapy.

Discussion

Eight patients affected by CSCC (three recurrent cases, three incompletely excised, and two previously untreated cases) were treated with topical 5-FU alone with remission of the disease after one or more courses of local chemotherapy.

The finding that surgical excision, alone or combined with cryotherapy, is sometimes not sufficient to eradicate conjunctival malignant tumours has been recently emphasised by Shields et al, who propose a systematic and radical surgical approach to these tumours.2 One of the major limitations of surgery alone is that margins which appear clinically free of disease at the time of surgery may, on later pathological examination, demonstrate infiltration by malignant cells. Moreover, the presence of free margins, both by clinical and pathological evaluation, does not guarantee that a conjunctival malignant tumour is completely eradicated, as reported by Erie et al for squamous tumours.3 These authors found that 40% of patients with invasive squamous cell carcinoma and 5% of patients with conjunctival intraepithelial neoplasm had local recurrence even if they had free surgical margins after primary excision. These figures increased to 100% and 53% respectively when the surgical margins were invaded by neoplasia. When neoplastic cells are identified at the margins of resection of a conjunctival carcinoma a wide resection of the surgical scar with adjuvant cryotherapy is indicated. The use of radiotherapy is of limited value in the treatment of recurrent squamous carcinoma of the conjunctiva because radiotherapy can give rise to ocular side effects5 6 and because the beneficial effects of radiotherapy are necessarily limited to the treated areas. Therefore, a treatment modality selective for neoplastic cells, wherever located in the entire conjunctiva, may represent an effective approach for the treatment of recurrent CSCC and some selected cases of untreated tumours—diffuse and poorly demarcated tumours, patients refusing surgery, or in poor health.

5-FU is currently used to inhibit the proliferation of subconjunctival fibroblasts after filtration surgery. There are only a few reports of its use as an antineoplastic drug for the treatment of ocular surface neoplasia.5 15 16 In 1986, de Keizer et al successfully treated with 5-FU eye drops (1%) two of three patients affected by carcinoma in situ of the conjunctiva and cornea.15 Topical 5-FU 1% was also used by Yeatts et al to treat three cases of carcinoma in situ, one case of invasive carcinoma, and two cases of conjunctival dysplasia.9 Surgical excision was used before topical chemotherapy in five of six cases. One patient treated for...
Treatment of conjunctival squamous cell carcinoma with topical 5-fluorouracil

corresponds with the guideline recently suggested by Grossniklaus and Aaberg for antineoplastic topical chemotherapy.11 This methodology allowed us to monitor the relatively long term effect (more than 15 months in eight patients, and more than 2 years in four of eight cases) of 5-FU chemotherapy in eradicating recurring or primary CSCC. Our data were not influenced by concomitant radical surgery or repeated biopsies which may be a confounding factor, as reported by Frucht-Pery et al.12,13 Thus our data show the efficacy of 5-FU alone. Moreover, all our patients had (untreated or recurrent) malignant tumours, because our aim was to evaluate the efficacy of topical chemotherapy for the treatment of malignant CSCC. Our decision to use 5-FU instead of mitomycin C, as recently proposed by other authors, was based on pharmacological and biological data.14 15 16 17 5-FU is a pyrimidine analogue commonly used to treat many epithelial cancers. It acts by interacting with S phase cells (those actively synthesising DNA).17 Therefore, it is suitable to treat squamous cell carcinoma because squamous tumours are composed of rapidly proliferating abnormal epithelial cells.18 It has limited side effects on the normal surface epithelium, as demonstrated by our results. 5-FU is an inexpensive drug, easily handled by medical personnel and patients, and is stable in aqueous solution for at least 3 weeks (Midena and Fregona, unpublished data). It does not need to be stored in a refrigerator, as does mitomycin C. On the other hand, mitomycin C is relatively unstable in solution and its action decreases in 8–10 days (Midena and Fregona, unpublished data). The acute and chronic side effects of mitomycin C are definitely much more frequent and serious than those induced by 5-FU, as referred to by clinicians using mitomycin C for pigmented conjunctival lesions (M Jager and MA Blasi, personal communications, 1999). Caution is advised in patients with conditions that predispose to epithelial dysfunction.19

The present study has some limitations. Firstly, the dosage of 5-FU was arbitrarily chosen after reviewing scanty literature data.14 15 16 17 Perhaps the 5-FU concentration can be increased to satisfy the general chemotherapy principle that each drug should be used at the highest tolerated dose.27 But no data exist in ophthalmic clinical practice about the safety of higher 5-FU dosage. Secondly, our mean follow up was 27 months. A longer follow up time is necessary to confirm the long term efficacy of our treatment modalities with respect to local tumour control.

We have used cytological specimens to monitor the morphological effects of our treatment on conjunctival lesions. Contrasting data and different opinions exist about the use of cytological smears to diagnose conjunctival malignancies.18–23 Glasgow and Foos questioned the use of cytological smears for grading conjunctival dysplasia.24 But Gelender and Forster,25 Paredaens et al.26 and Naib27 have used this method with satisfactory results. We have used cytological specimens for the past 15 years to obtain valuable information regarding premalignant and malignant lesions of the conjunctiva.24 25 Moreover, the cytological collection obtained with the scraping technique we described is well accepted by the patient and may be repeated as many times as necessary without inducing morphological alterations in the sampled area. We agree that histopathology is superior to cytology to define the type and depth of invasion of any conjunctival neoplastic lesion, but we are not convinced that conjunctival biopsy is the best method to sequentially sample small conjunctival areas without becoming an excisional surgical modality itself. This method may limit the possibility of monitoring correctly the sequence of events induced by 5-FU chemotherapy on conjunctival neoplastic areas.18 In any case, six of the eight patients underwent a final surgical biopsy, which confirmed the cytological results.

This was a prospective but not a randomised study. The aim of this study was merely to test the efficacy of topical 5-FU for the treatment of CSCC in clinical situations where an alternative to surgery or adjunctive treatment is required. This pilot study does not advocate that topical 5-FU should be used routinely in the treatment of conjunctival squamous cell carcinoma, but it shows that topical chemotherapy with 5-FU alone was effective in eradicating CSCC in our patients, without major and/or long term side effects. Therefore, the use of topical 5-FU should be more widely investigated, in prospective randomised trials, to define its role in the treatment of recurrent or selected untreated CSCC.